PA
TAK icon

Parallel Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Parallel Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Buy
28,293
+3,642
+15% +$60.3K 0.01% 835
2026
Q1 		$457K Buy
24,651
+2,343
+11% +$41.1K 0.01% 760
2025
Q4 		$348K Sell
22,308
-1,529
-6% -$21.9K 0.01% 835
2025
Q3 		$349K Sell
23,837
-501
-2% -$7.44K 0.01% 795
2025
Q2 		$376K Buy
24,338
+4,485
+23% +$66.3K 0.01% 740
2025
Q1 		$295K Buy
19,853
+3,479
+21% +$48.7K 0.01% 788
2024
Q4 		$217K Buy
16,374
+6,977
+74% +$95.8K ﹤0.01% 896
2024
Q3 		$134K Buy
9,397
+3,822
+69% +$54.2K ﹤0.01% 1128
2024
Q2 		$72.1K Sell
5,575
-894
-14% -$11.8K ﹤0.01% 1340
2024
Q1 		$89.9K Buy
6,469
+1,089
+20% +$15.8K ﹤0.01% 1221
2023
Q4 		$76.8K Sell
5,380
-1,780
-25% -$25.3K ﹤0.01% 1237
2023
Q3 		$111K Buy
7,160
+552
+8% +$8.54K ﹤0.01% 1035
2023
Q2 		$104K Buy
6,608
+1,533
+30% +$25.1K ﹤0.01% 1052
2023
Q1 		$83.6K Buy
5,075
+1,623
+47% +$25.9K ﹤0.01% 1128
2022
Q4 		$53.9K Sell
3,452
-7,904
-70% -$110K ﹤0.01% 1245
2022
Q3 		$147K Buy
11,356
+640
+6% +$8.9K 0.01% 792
2022
Q2 		$150K Buy
10,716
+644
+6% +$9.19K 0.01% 799
2022
Q1 		$145K Buy
10,072
+2,817
+39% +$41.4K 0.01% 845
2021
Q4 		$99K Buy
7,255
+1,342
+23% +$18.8K ﹤0.01% 1023
2021
Q3 		$97K Buy
5,913
+1,377
+30% +$23.1K ﹤0.01% 998
2021
Q2 		$76K Sell
4,536
-222
-5% -$3.78K ﹤0.01% 1045
2021
Q1 		$87K Buy
4,758
+954
+25% +$17.2K ﹤0.01% 943
2020
Q4 		$69K Sell
3,804
-597
-14% -$10.5K ﹤0.01% 961
2020
Q3 		$79K Sell
4,401
-113
-3% -$2.06K ﹤0.01% 871
2020
Q2 		$80K Buy
4,514
+2,009
+80% +$36.1K 0.01% 855
2020
Q1 		$38K Buy
2,505
+542
+28% +$9.82K ﹤0.01% 1040
2019
Q4 		$39K Buy
1,963
+454
+30% +$8.69K ﹤0.01% 1122
2019
Q3 		$26K Buy
1,509
+1,108
+276% +$19.2K ﹤0.01% 1245
2019
Q2 		$7K Sell
401
-1,222
-75% -$22.2K ﹤0.01% 1731
2019
Q1 		$33K Buy
+1,623
New +$32.7K ﹤0.01% 1023

Other funds holding TAK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Managed Asset Portfolios Rochester, Michigan $875M AUM 41.9% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Parallel Advisors's TAK Position: Q2 2026 in Review

Parallel Advisors increased its Takeda Pharmaceutical (TAK) stake by 15% in Q2 2026, buying an estimated $60.3K and bringing the position to 28,293 shares worth $454K. The position accounts for 0.01% of the portfolio, ranked #835.

Parallel Advisors first reported a position in TAK in Q1 2019 and has held it in 30 quarters since. The position peaked at $457K in Q1 2026. 201 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Parallel Advisors held 28,293 shares of Takeda Pharmaceutical worth $454K as of Q2 2026.
  • Parallel Advisors bought 3,642 Takeda Pharmaceutical shares in Q2 2026, an estimated $60.3K.
  • Takeda Pharmaceutical made up 0.01% of Parallel Advisors's portfolio in Q2 2026, its #835 holding.
  • Parallel Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
  • Parallel Advisors's Takeda Pharmaceutical position peaked at $457K in Q1 2026.
  • 201 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.